{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:56:15Z","timestamp":1791338175579,"version":"4.3.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-025-01571-x","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T10:51:47Z","timestamp":1738061507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Investigating the significance of SPECT\/CT-SUV for monitoring 177Lu-PSMA-targeted radionuclide therapy: a systematic review"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-5337","authenticated-orcid":false,"given":"Tahani O.","family":"Alkahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"1571_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel R. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1571_CR2","doi-asserted-by":"publisher","unstructured":"Bohn K, F\u00fcrstner M, Hentschel M, Mingels C, Alberts I, Rominger A, et al. Pharmacokinetics of PSMA-617 \u2013 dynamics of radiopharmaceutical uptake in tumours. 59. Jahrestagung der Deutschen Gesellschaft f\u00fcr Nuklearmedizin. 2021;60. https:\/\/doi.org\/10.1055\/s-0041-1727070.","DOI":"10.1055\/s-0041-1727070"},{"key":"1571_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59:469\u201378. https:\/\/doi.org\/10.2967\/jnumed.117.198119.","journal-title":"J Nucl Med"},{"key":"1571_CR4","unstructured":"U.S. Food & Drug Administration. FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer. Accessed 18 July 2024."},{"key":"1571_CR5","doi-asserted-by":"publisher","unstructured":"Jones W, Griffiths K, Barata PC, Paller CJ. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers (Basel). 2020;12. https:\/\/doi.org\/10.3390\/cancers12061367.","DOI":"10.3390\/cancers12061367"},{"key":"1571_CR6","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697\u2013705. https:\/\/doi.org\/10.2967\/jnumed.115.161299.","journal-title":"J Nucl Med"},{"key":"1571_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/J.YMETH.2017.06.026","volume":"130","author":"S L\u00fctje","year":"2017","unstructured":"L\u00fctje S, Slavik R, Fendler W, Herrmann K, Eiber M. PSMA ligands in prostate cancer \u2013 Probe optimization and theranostic applications. Methods. 2017;130:42\u201350. https:\/\/doi.org\/10.1016\/J.YMETH.2017.06.026.","journal-title":"Methods"},{"key":"1571_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJMECH.2023.115966","volume":"263","author":"G Capasso","year":"2024","unstructured":"Capasso G, Stefanucci A, Tolomeo A. A systematic review on the current status of PSMA-targeted imaging and radioligand therapy. Eur J Med Chem. 2024;263: 115966. https:\/\/doi.org\/10.1016\/J.EJMECH.2023.115966.","journal-title":"Eur J Med Chem"},{"key":"1571_CR9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388. https:\/\/doi.org\/10.1007\/s00259-016-3573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR10","doi-asserted-by":"publisher","DOI":"10.4274\/mirt.30502","author":"MF Bozkurt","year":"2018","unstructured":"Bozkurt MF, \u00d6zcan Z. The Evolving Role of Nuclear Medicine and Molecular Imaging: Theranostics and Personalized Therapeutic Applications. Malecular Imaging and Radionuclide Therapy. 2018. https:\/\/doi.org\/10.4274\/mirt.30502.","journal-title":"Malecular Imaging and Radionuclide Therapy"},{"key":"1571_CR11","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.7150\/thno.92273","volume":"14","author":"A Schaefer-Schuler","year":"2024","unstructured":"Schaefer-Schuler A, Burgard C, Blickle A, Maus S, Petrescu C, Petto S, et al. [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617. Theranostics. 2024;14:1829\u201340. https:\/\/doi.org\/10.7150\/thno.92273.","journal-title":"Theranostics"},{"key":"1571_CR12","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.2967\/jnumed.120.258376","volume":"62","author":"RP Baum","year":"2021","unstructured":"Baum RP, Singh A, Kulkarni HR, Bernhardt P, Ryd\u00e9n T, Schuchardt C, et al. First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC. J Nucl Med. 2021;62:1391\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.258376.","journal-title":"J Nucl Med"},{"key":"1571_CR13","doi-asserted-by":"publisher","unstructured":"Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64. https:\/\/doi.org\/10.1002\/jmrs.227.","DOI":"10.1002\/jmrs.227"},{"key":"1571_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Bene\u0161ov\u00e1","year":"2015","unstructured":"Bene\u0161ov\u00e1 M, Sch\u00e4fer M, Bauder-W\u00fcst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med. 2015;56:914\u201320. https:\/\/doi.org\/10.2967\/jnumed.114.147413.","journal-title":"J Nucl Med"},{"key":"1571_CR15","first-page":"555","volume":"28","author":"M Santoni","year":"2014","unstructured":"Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents. 2014;28:555\u201363.","journal-title":"J Biol Regul Homeost Agents."},{"key":"1571_CR16","doi-asserted-by":"publisher","unstructured":"Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, et al. 68Ga-PSMA-11 PET\/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann Nucl Med. 2019;33. https:\/\/doi.org\/10.1007\/s12149-019-01387-0.","DOI":"10.1007\/s12149-019-01387-0"},{"key":"1571_CR17","doi-asserted-by":"publisher","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, et al. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. J Nucl Med. 2019;60(4):517\u201323. https:\/\/doi.org\/10.2967\/jnumed.118.219352.\u00a0Epub 5 Oct 2018.","DOI":"10.2967\/jnumed.118.219352"},{"key":"1571_CR18","doi-asserted-by":"publisher","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol 2022;23. https:\/\/doi.org\/10.1016\/S1470-2045(22)00605-2.","DOI":"10.1016\/S1470-2045(22)00605-2"},{"key":"1571_CR19","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s00259-017-3716-2","volume":"44","author":"H Ahmadzadehfar","year":"2017","unstructured":"Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, K\u00fcrpig S, Eppard E, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44:1448\u201354. https:\/\/doi.org\/10.1007\/s00259-017-3716-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2967\/jnumed.116.178228","volume":"58","author":"J Ferdinandus","year":"2017","unstructured":"Ferdinandus J, Eppard E, Gaertner FC, K\u00fcrpig S, Fimmers R, Yordanova A, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med. 2017;58:312\u20139. https:\/\/doi.org\/10.2967\/jnumed.116.178228.","journal-title":"J Nucl Med"},{"key":"1571_CR21","doi-asserted-by":"publisher","unstructured":"De Giorgi U, Sansovini M, Severi S, Nicolini S, Monti M, Gurioli G, et al. Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. Br J Cancer. 2021;125. https:\/\/doi.org\/10.1038\/s41416-021-01508-5.","DOI":"10.1038\/s41416-021-01508-5"},{"key":"1571_CR22","doi-asserted-by":"publisher","unstructured":"O JH, Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology. 2016;280:576\u201384. https:\/\/doi.org\/10.1148\/radiol.2016142043.","DOI":"10.1148\/radiol.2016142043"},{"key":"1571_CR23","unstructured":"U.S. FDA & Drug Adminisrtation. FDA approves Pluvicto for metastatic castration-resistant prostate cancer 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer. Accessed 18 July 2024."},{"key":"1571_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40644-024-00702-x","volume":"24","author":"N Ayati","year":"2024","unstructured":"Ayati N, McIntosh L, Buteau J, Alipour R, Pudis M, Daw N, et al. Comparison of quantitative whole body PET parameters on [68Ga]Ga-PSMA-11 PET\/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer. Cancer Imaging. 2024;24:57. https:\/\/doi.org\/10.1186\/s40644-024-00702-x.","journal-title":"Cancer Imaging"},{"key":"1571_CR25","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2967\/jnumed.123.267014","volume":"65","author":"M Swiha","year":"2024","unstructured":"Swiha M, Papa N, Sabahi Z, Ayati N, John N, Pathmanandavel S, et al. Development of a visually calculated SUVmean (HIT Score) on screening PSMA PET\/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes. J Nucl Med. 2024;65:904\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.267014.","journal-title":"J Nucl Med"},{"key":"1571_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/bmj.n160","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ. 2020;2021:372. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"key":"1571_CR27","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00259-023-06476-x","volume":"51","author":"C Burgard","year":"2024","unstructured":"Burgard C, Hein C, Blickle A, Bartholom\u00e4 M, Maus S, Petto S, et al. Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry. Eur J Nucl Med Mol Imaging. 2024;51:885\u201395. https:\/\/doi.org\/10.1007\/s00259-023-06476-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR28","doi-asserted-by":"publisher","first-page":"1339160","DOI":"10.3389\/fmed.2023.1339160","volume":"10","author":"C Burgard","year":"2023","unstructured":"Burgard C, Engler J, Blickle A, Bartholom\u00e4 M, Maus S, Schaefer-Schuler A, et al. Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker. Front Med (Lausanne). 2023;10:1339160. https:\/\/doi.org\/10.3389\/fmed.2023.1339160.","journal-title":"Front Med (Lausanne)"},{"key":"1571_CR29","doi-asserted-by":"publisher","unstructured":"Kim M, Seifert R, Fragemann J, Kersting D, Murray J, Jonske F, et al. Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2023;50. https:\/\/doi.org\/10.1007\/s00259-023-06163-x.","DOI":"10.1007\/s00259-023-06163-x"},{"key":"1571_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13550-023-01033-x","volume":"13","author":"J Heilinger","year":"2023","unstructured":"Heilinger J, Weindler J, Roth KS, Krapf P, Schom\u00e4cker K, Dietlein M, et al. Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer. EJNMMI Res. 2023;13:83. https:\/\/doi.org\/10.1186\/s13550-023-01033-x.","journal-title":"EJNMMI Res"},{"key":"1571_CR31","doi-asserted-by":"publisher","unstructured":"Gaudreault M, Chang D, Hardcastle N, Jackson P, Kron T, Hofman MS, et al. Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer. Front Oncol. 2023;13. https:\/\/doi.org\/10.3389\/fonc.2023.1134884.","DOI":"10.3389\/fonc.2023.1134884"},{"key":"1571_CR32","doi-asserted-by":"publisher","unstructured":"van der Sar ECA, K\u00fchr AJS, Ebbers SC, Henderson AM, Keizer B de, Lam MGEH, et al. Baseline imaging derived predictive factors of response following [177 Lu]Lu-PSMA-617 therapy in salvage metastatic castration-resistant prostate cancer: a lesion- and patient-based analysis. Biomedicines. 2022;10. https:\/\/doi.org\/10.3390\/biomedicines10071575.","DOI":"10.3390\/biomedicines10071575"},{"key":"1571_CR33","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00259-021-05538-2","volume":"49","author":"SMB Peters","year":"2022","unstructured":"Peters SMB, Hofferber R, Priv\u00e9 BM, de Bakker M, Gotthardt M, Janssen M, et al. [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49:1101\u201312. https:\/\/doi.org\/10.1007\/s00259-021-05538-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR34","doi-asserted-by":"publisher","unstructured":"Khreish F, Wiessner M, Rosar F, Ghazal Z, Sabet A, Maus S, et al. Response assessment and prediction of progression-free survival by68ga-psma-11 pet\/ct based on tumor-to-liver ratio (Tlr) in patients with mcrpc undergoing177lu-psma-617 radioligand therapy. Biomolecules. 2021;11. https:\/\/doi.org\/10.3390\/biom11081099.","DOI":"10.3390\/biom11081099"},{"key":"1571_CR35","doi-asserted-by":"publisher","first-page":"8143","DOI":"10.7150\/THNO.60222","volume":"11","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weckesser M, Kersting D, Seitzer KE, et al. Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy. Theranostics. 2021;11:8143\u201351. https:\/\/doi.org\/10.7150\/THNO.60222.","journal-title":"Theranostics"},{"key":"1571_CR36","doi-asserted-by":"publisher","unstructured":"Junqueira MZ, Rocha NH, Sapienza MT. 68ga-psma pet\/ct: effect of external cooling on salivary gland uptake. Radiol Bras. 2021;54. https:\/\/doi.org\/10.1590\/0100-3984.2020.0044.","DOI":"10.1590\/0100-3984.2020.0044"},{"key":"1571_CR37","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.7150\/thno.47251","volume":"10","author":"R Seifert","year":"2020","unstructured":"Seifert R, Seitzer K, Herrmann K, Kessel K, Sch\u00e4fers M, Kleesiek J, et al. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy. Theranostics. 2020;10:7812\u201320. https:\/\/doi.org\/10.7150\/thno.47251.","journal-title":"Theranostics"},{"key":"1571_CR38","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00259-019-04583-2","volume":"47","author":"J Maffey-Steffan","year":"2020","unstructured":"Maffey-Steffan J, Scarpa L, Svirydenka A, Nilica B, Mair C, Buxbaum S, et al. The 68Ga\/177Lu-theragnostic concept in PSMA-targeting of metastatic castration\u2013resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Eur J Nucl Med Mol Imaging. 2020;47:695\u2013712. https:\/\/doi.org\/10.1007\/s00259-019-04583-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR39","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.3390\/cancers15153878","volume":"15","author":"D Groener","year":"2023","unstructured":"Groener D, Wichert J, Adams M, Mader N, Klimek K, Nguyen Ngoc C, et al. Impact of [177Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [68Ga]Ga-PSMA-11-PET\/CT. Cancers (Basel). 2023;15:3878. https:\/\/doi.org\/10.3390\/cancers15153878.","journal-title":"Cancers (Basel)"},{"key":"1571_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2967\/jnumed.122.264857","volume":"64","author":"G Wang","year":"2023","unstructured":"Wang G, Zang J, Jiang Y, Liu Q, Sui H, Wang R, et al. A Single-Arm, Low-Dose, Prospective Study of 177 Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2023;64:611\u20137. https:\/\/doi.org\/10.2967\/jnumed.122.264857.","journal-title":"J Nucl Med"},{"key":"1571_CR41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2967\/jnumed.122.264342","volume":"64","author":"C Civan","year":"2023","unstructured":"Civan C, Kasper S, Berliner C, Fragoso-Costa P, Gr\u00fcnwald V, Pogorzelski M, et al. PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study. J Nucl Med. 2023;64:372\u20138. https:\/\/doi.org\/10.2967\/jnumed.122.264342.","journal-title":"J Nucl Med"},{"key":"1571_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.nucmedbio.2021.12.003","volume":"106\u2013107","author":"R Imura","year":"2022","unstructured":"Imura R, Ozeki AN, Shida N, Kobayashi M, Ida H, Wada Y, et al. Radiolabeling of PSMA-617 with 89Zr: A novel use of DMSO to improve radiochemical yield and preliminary small-animal PET results. Nucl Med Biol. 2022;106\u2013107:21\u20138. https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.12.003.","journal-title":"Nucl Med Biol"},{"key":"1571_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2967\/jnmt.120.261289","volume":"49","author":"A Kalshetty","year":"2021","unstructured":"Kalshetty A, Menon B, Rakshit S, Bhattacharjee A, Basu S. Correlation of lesional uptake parameters and ratios with miPSMA score and estimating normal physiologic concentration: an exploratory analysis in metastatic castration-resistant prostatic carcinoma patients with 68 Ga-PSMA-11 PET\/CT. J Nucl Med Technol. 2021;49:235\u201340. https:\/\/doi.org\/10.2967\/jnmt.120.261289.","journal-title":"J Nucl Med Technol"},{"key":"1571_CR44","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.3390\/cancers13164134","volume":"13","author":"F Khreish","year":"2021","unstructured":"Khreish F, Ribbat K, Bartholom\u00e4 M, Maus S, Stemler T, Hierlmeier I, et al. Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC patients with worsening disease during [177Lu]Lu-PSMA-617 RLT. Cancers (Basel). 2021;13:4134. https:\/\/doi.org\/10.3390\/cancers13164134.","journal-title":"Cancers (Basel)"},{"key":"1571_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.euros.2021.06.007","volume":"30","author":"J Stangl-Kremser","year":"2021","unstructured":"Stangl-Kremser J, Rasul S, Tosoian JJ, Salami SS, Zaslavsky A, Udager A, et al. Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. Eur Urol Open Sci. 2021;30:63\u20136. https:\/\/doi.org\/10.1016\/j.euros.2021.06.007.","journal-title":"Eur Urol Open Sci"},{"key":"1571_CR46","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","volume":"48","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48:1200\u201310. https:\/\/doi.org\/10.1007\/s00259-020-05040-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR47","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2967\/jnumed.118.222307","volume":"60","author":"NJ Rupp","year":"2019","unstructured":"Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, T\u00f6pfer A, M\u00fcller J, et al. First Clinicopathologic Evidence of a Non\u2013PSMA-Related Uptake Mechanism for 68 Ga-PSMA-11 in Salivary Glands. J Nucl Med. 2019;60:1270\u20136. https:\/\/doi.org\/10.2967\/jnumed.118.222307.","journal-title":"J Nucl Med"},{"key":"1571_CR48","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s00259-017-3791-4","volume":"44","author":"F Matteucci","year":"2017","unstructured":"Matteucci F, Mezzenga E, Caroli P, Di Iorio V, Sarnelli A, Celli M, et al. Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results. Eur J Nucl Med Mol Imaging. 2017;44:2189\u201394. https:\/\/doi.org\/10.1007\/s00259-017-3791-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1055\/a-1035-9052","volume":"58","author":"K Michalski","year":"2019","unstructured":"Michalski K, Mix M, Meyer PT, Ruf J. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET\/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy. Nuklearmedizin. 2019;58:443\u201350. https:\/\/doi.org\/10.1055\/a-1035-9052.","journal-title":"Nuklearmedizin"},{"key":"1571_CR50","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1002\/mp.14936","volume":"48","author":"L Mel\u00e9ndez-Alafort","year":"2021","unstructured":"Mel\u00e9ndez-Alafort L, Ferro-Flores G, Santos-Cuevas C, Ocampo-Garc\u00eda B, Turato S, Fracasso G, et al. Preclinical dosimetric studies of 177Lu-scFvD2B and comparison with 177Lu-PSMA-617 and 177Lu-iPSMA endoradiotherapeutic agents. Med Phys. 2021;48:4064\u201374. https:\/\/doi.org\/10.1002\/mp.14936.","journal-title":"Med Phys"},{"key":"1571_CR51","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s00259-024-06718-6","volume":"51","author":"H Song","year":"2024","unstructured":"Song H, Leonio MI, Ferri V, Duan H, Aparici CM, Davidzon G, et al. Same-day post-therapy imaging with a new generation whole-body digital SPECT\/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51:2784\u201393. https:\/\/doi.org\/10.1007\/s00259-024-06718-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR52","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/RLU.0000000000002575","volume":"44","author":"J Wang","year":"2019","unstructured":"Wang J, Zang J, Wang H, Liu Q, Li F, Lin Y, et al. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions. Clin Nucl Med. 2019;44:431\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000002575.","journal-title":"Clin Nucl Med"},{"key":"1571_CR53","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","volume":"51","author":"MC Neubauer","year":"2024","unstructured":"Neubauer MC, Nicolas GP, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, et al. Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. Eur J Nucl Med Mol Imaging. 2024;51:1185\u201393. https:\/\/doi.org\/10.1007\/s00259-023-06536-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR54","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/jnumed.122.264398","volume":"64","author":"S Pathmanandavel","year":"2023","unstructured":"Pathmanandavel S, Crumbaker M, Ho B, Yam AO, Wilson P, Niman R, et al. Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). J Nucl Med. 2023;64:221\u20136. https:\/\/doi.org\/10.2967\/jnumed.122.264398.","journal-title":"J Nucl Med"},{"key":"1571_CR55","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2967\/jnumed.123.265763","volume":"64","author":"M Grkovski","year":"2023","unstructured":"Grkovski M, O\u2019Donoghue JA, Imber BS, Andl G, Tu C, Lafontaine D, et al. Lesion Dosimetry for [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer. J Nucl Med. 2023;64:1779\u201387. https:\/\/doi.org\/10.2967\/jnumed.123.265763.","journal-title":"J Nucl Med"},{"key":"1571_CR56","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"1571_CR57","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","volume":"50","author":"PE Hartrampf","year":"2023","unstructured":"Hartrampf PE, H\u00fcttmann T, Seitz AK, K\u00fcbler H, Serfling SE, Schl\u00f6telburg W, et al. SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T. Eur J Nucl Med Mol Imaging. 2023;50:3465\u201374. https:\/\/doi.org\/10.1007\/s00259-023-06281-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR58","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s00259-016-3609-9","volume":"44","author":"L Scarpa","year":"2017","unstructured":"Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, et al. The 68Ga\/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. Eur J Nucl Med Mol Imaging. 2017;44:788\u2013800. https:\/\/doi.org\/10.1007\/s00259-016-3609-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR59","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/RLU.0000000000001480","volume":"42","author":"W Roll","year":"2017","unstructured":"Roll W, Bode A, Weckesser M, B\u00f6gemann M, Rahbar K. Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient with Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET\/CT. Clin Nucl Med. 2017;42:152\u20133. https:\/\/doi.org\/10.1097\/RLU.0000000000001480.","journal-title":"Clin Nucl Med"},{"key":"1571_CR60","doi-asserted-by":"publisher","unstructured":"Einspieler H, Kluge K, Haberl D, Schatz K, Nics L, Schmitl S, et al. Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [68Ga]Ga-PSMA-11-PET Examinations. Cancers (Basel). 2024;16. https:\/\/doi.org\/10.3390\/cancers16081514.","DOI":"10.3390\/cancers16081514"},{"key":"1571_CR61","doi-asserted-by":"publisher","unstructured":"Grubm\u00fcller B, Senn D, Kramer G, Baltzer P, D\u2019Andrea D, Eidherr H, et al. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration resistant prostate cancer. Eur Urol Suppl. 2019;18. https:\/\/doi.org\/10.1016\/s1569-9056(19)30513-5.","DOI":"10.1016\/s1569-9056(19)30513-5"},{"key":"1571_CR62","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","volume":"46","author":"B Grubm\u00fcller","year":"2019","unstructured":"Grubm\u00fcller B, Senn D, Kramer G, Baltzer P, D\u2019Andrea D, Grubm\u00fcller KH, et al. Response assessment using 68 Ga-PSMA ligand PET in patients undergoing 177 Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1063\u201372. https:\/\/doi.org\/10.1007\/s00259-018-4236-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR63","doi-asserted-by":"publisher","unstructured":"Moazemi S, Erle A, L\u00fctje S, Gaertner FC, Essler M, Bundschuh RA. Estimating the potential of radiomics features and radiomics signature from pretherapeutic PSMA-PET-CT scans and clinical data for prediction of overall survival when treated with 177Lu-PSMA. Diagnostics. 2021;11. https:\/\/doi.org\/10.3390\/diagnostics11020186.","DOI":"10.3390\/diagnostics11020186"},{"key":"1571_CR64","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","volume":"47","author":"J Ferdinandus","year":"2020","unstructured":"Ferdinandus J, Violet J, Sandhu S, Hicks RJ, Ravi Kumar AS, Iravani A, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47:2322\u20137. https:\/\/doi.org\/10.1007\/s00259-020-04723-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR65","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","volume":"57","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy. J Nucl Med. 2016;57:1006\u201313. https:\/\/doi.org\/10.2967\/jnumed.115.168443.","journal-title":"J Nucl Med"},{"key":"1571_CR66","doi-asserted-by":"publisher","unstructured":"Rosar F, Sch\u00f6n N, Bohnenberger H, Bartholom\u00e4 M, Stemler T, Maus S, et al. Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy. EJNMMI Phys. 2021;8. https:\/\/doi.org\/10.1186\/s40658-021-00385-4.","DOI":"10.1186\/s40658-021-00385-4"},{"key":"1571_CR67","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","volume":"42","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, AbuQbeitah M, Ayg\u00fcn A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1976\u201383. https:\/\/doi.org\/10.1007\/s00259-015-3125-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1571_CR68","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2967\/jnumed.116.178483","volume":"58","author":"S Okamoto","year":"2017","unstructured":"Okamoto S, Thieme A, Allmann J, D\u2019Alessandria C, Maurer T, Retz M, et al. Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: Absorbed dose in normal organs and tumor lesions. J Nucl Med. 2017;58:445\u201350. https:\/\/doi.org\/10.2967\/jnumed.116.178483.","journal-title":"J Nucl Med"},{"key":"1571_CR69","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13139-021-00713-7","volume":"55","author":"E Mahmoudi","year":"2021","unstructured":"Mahmoudi E, Pirayesh E, Deevband MR, Amoui M, Rad MG, Ghorbani M. Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617. Nucl Med Mol Imaging. 2021;55:237\u201344. https:\/\/doi.org\/10.1007\/s13139-021-00713-7.","journal-title":"Nucl Med Mol Imaging"},{"key":"1571_CR70","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42\u201351. https:\/\/doi.org\/10.1007\/s00259-015-3174-7.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01571-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T21:58:48Z","timestamp":1738101528000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-025-01571-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01571-x","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}